Factors Causing False-Positive Alzheimer's Blood Biomarker Results
False-positive Alzheimer's blood biomarker results are primarily caused by stroke, high comorbidity burden (Charlson Comorbidity Index ≥2), and pre-analytical sample handling errors, with renal dysfunction also significantly affecting biomarker levels.
Key Clinical Factors That Cause False Positives
Patient-Specific Medical Conditions
Stroke is the most significant factor reducing diagnostic accuracy of blood biomarkers, particularly affecting p-tau217, Aβ42/40, and combined biomarker panels 1. When patients have a history of stroke, the association between plasma biomarkers and actual amyloid pathology becomes unreliable.
High comorbidity burden (Charlson Comorbidity Index ≥2) substantially reduces the performance of biomarker panels 1. This is critical because many elderly patients presenting with cognitive concerns have multiple medical conditions.
Renal function is a major confounding factor:
- P-tau217 levels are significantly influenced by renal function 2
- Neurofilament light chain (NfL) is particularly affected by kidney function 2
- Impaired renal clearance can elevate biomarker levels independent of brain pathology
Demographic and Physiological Factors
Age and sex independently affect biomarker levels:
- GFAP is primarily predicted by age and sex rather than amyloid pathology alone 2
- NfL levels are influenced by age, sex, and renal function 2
Body mass index (BMI) shows an inverse relationship:
- Lower BMI is associated with higher p-tau217 and p-tau181 levels regardless of cognitive symptoms 3
- However, BMI does not appear to be a true confounding variable but rather may reflect disease-related weight loss 3
Pre-Analytical Factors
Sample handling and processing errors are critical sources of false results 4, 5, 6:
- Inconsistent blood collection protocols
- Improper storage conditions
- Variable processing procedures
- Lack of standardized operating procedures
The 2026 Chinese guidelines specifically emphasize that β-amyloid protein and phosphorylated tau protein detection are "highly susceptible to pre-analysis factors, which reduces the reliability of their clinical application" 6.
Understanding Test Performance Context
The reference standard matters: Blood biomarkers are validated against amyloid PET, which itself has imperfect specificity (89-100% depending on tracer) 4. This means a "false positive" blood test may actually reflect true amyloid pathology that hasn't yet caused cognitive symptoms.
Population prevalence affects interpretation: The same test will have different positive predictive values in different settings 7. In populations with lower AD prevalence (like primary care), more positive results will be false positives compared to specialized memory clinics.
Clinical Pitfalls to Avoid
Do not rely solely on blood biomarkers in patients with:
- Recent or remote stroke history
- Charlson Comorbidity Index ≥2
- Significant renal impairment
Account for demographic factors:
- Older age naturally elevates GFAP and NfL
- Sex differences affect baseline biomarker levels
- Race/ethnicity may require different biomarker panels 8
Ensure proper pre-analytical procedures:
- Use standardized blood collection protocols
- Maintain consistent storage conditions
- Follow manufacturer specifications exactly
Remember that blood biomarkers detect amyloid pathology, not dementia:
- A positive test indicates brain amyloid accumulation
- This may precede cognitive symptoms by years
- Clinical correlation is essential 9
Specific Biomarker Vulnerabilities
- P-tau217: Most affected by stroke and renal function
- Aβ42/40: Reduced accuracy after stroke; enhanced by hypercholesterolemia 1
- GFAP: Primarily reflects age and sex rather than specific AD pathology
- NfL: Heavily influenced by renal function and age; non-specific for AD
The most robust approach is using p-tau217 or %p-tau217 in patients without stroke, with CCI <2, and normal renal function, as these achieve AUCs of 0.92-0.98 for detecting amyloid pathology 4.